Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Computer conglomerate IBM has teamed up with technology providers as part of an initiative to develop new software aimed at transforming the development and manufacturing capabilities of large pharmaceutical and biotech companies.
Subscribe to our email newsletter
IBM’s Healthcare and Life Sciences unit said it has developed a framework, called Proof of Concept (PoC), that demonstrates how the Food and Drug Administration’s (FDA) Science of Design and Manufacturing Science concepts can be enabled in a Service Oriented Architecture (SOA).
“The business transformation is highly complex, and the route map of activities and changes an organization needs to take is not always clear,” explained Steve Arlington, global pharmaceutical industry leader, IBM Business Consulting Services. “Companies need a framework to help take them to the end state of higher production efficiency, lower operational costs, and effective regulatory compliance.”
IBM claims that the top 30 Pharma companies can protect up to $60bn of future revenues, accelerate time to peak sales by two years and reduce Cost of Goods Sold (COGS) by up to 16% by managing risk and applying scientific- and systems-based approaches throughout development and manufacturing.